论文部分内容阅读
目的:探讨年龄及性别因素对癫痫患儿奥卡西平代谢产物血药浓度的影响。方法:采用高效液相色谱法(HPLC)对217例服用奥卡西平的儿童癫痫患儿进行奥卡西平活性代谢产物(MHD)血清稳态质量浓度测定,分析其血清浓度与年龄、性别的关系。结果:在推荐剂量8～46 mg/(kg.d)范围内,服用奥卡西平的患儿血清MHD质量浓度随着年龄增长有升高趋势,但差异无统计学意义(P>0.05);相同条件下,不同性别组患儿血清MHD质量浓度差异无统计学意义(P>0.05)。结论:在推荐剂量范围内,奥卡西平活性代谢产物的血清质量浓度与性别无相关性,虽随年龄增加而升高,但差异无统计学意义。因此选用奥卡西平治疗癫痫患儿时应定期进行血药浓度监测,及时调整用药剂量,尽量实现个体化用药。
Objective: To investigate the effect of age and gender on the blood concentration of oxcarbazepine metabolites in children with epilepsy. Methods: Serum steady-state concentrations of active metabolites of oxcarbazepine (217) were determined in 217 children with epilepsy by using high performance liquid chromatography (HPLC). The relationship between serum concentration and age and sex was analyzed . Results: The levels of MHD in children with oxcarbazepine tended to increase with age at the recommended dose of 8 to 46 mg / (kg · d), but the difference was not statistically significant (P> 0.05). Under the same conditions, there was no significant difference in serum MHD concentration between children of different genders (P> 0.05). CONCLUSION: There is no correlation between the serum concentration of active metabolites of oxcarbazepine and sex in the recommended dosage range, although it increases with age, but the difference is not statistically significant. Therefore, the selection of oxcarbazepine treatment of children with epilepsy should be regularly monitored blood concentration, timely adjustment of dosage, try to achieve individualized medication.